title: Control of Candida albicans vaginitis in mice by short-duration butoconazole treatment in situ.
abstract: A short-duration treatment for candidal vaginitis applying butoconazole in situ was tested in an experimental mouse model. One week after artificial induction of an oestrus state (by oestradiol benzoate injection), mice were inoculated intravaginally with 1.5 x 10(7) blastospores of Candida albicans (strain ATCC 44858). Treatment consisted of butoconazole solutions (1%, 2.5% and 5%) administered intravaginally. The development of the infection was monitored daily for 12 days and then three times a week by local samples plated on BiGGY agar. In parallel, twice a week, the vaginas of three mice in each group (control and treated groups) were isolated in order to estimate organ invasion by C. albicans. This was assessed by anatomopathological studies on a fixed and stained part of the organ and by serial dilutions of a homogenate of the remaining part plated on Sabouraud glucose chloramphenicol agar. After a 48-h incubation period the number of colony forming units per gram of tissue was counted. For each treatment, a remission of 10-15 days was observed, but was followed by a recurrence for the lower dose of butoconazole; only the higher butoconazole concentrations tested (2.5% and 5%) gave an apparent full cure for most of the mice tested. The use of the mouse model of candidal vaginitis confirms that short-duration treatment is possible when elevated doses of butoconazole are used.
authors.affiliation: Laboratoire d'Immunologie et Parasitologie, Faculté de Pharmacie, Montpellier, France.
authors.forename: A
authors.initials: A
authors.lastname: Valentin
authors.forename: C
authors.initials: C
authors.lastname: Bernard
authors.forename: M
authors.initials: M
authors.lastname: Mallié
authors.forename: M
authors.initials: M
authors.lastname: Huerre
authors.forename: J M
authors.initials: JM
authors.lastname: Bastide
mesh_terms: D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy* / Q000382:microbiology; D015169:Colony Count, Microbial; D004305:Dose-Response Relationship, Drug; D005260:Female; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D013997:Time Factors; D014621:Vagina / Q000382:microbiology
chemical_list: D000935:Antifungal Agents; D007093:Imidazoles; C017125:butoconazole